The world’s leading physiologic EFA expert — Prof. Brian Peskin Prof. Brian Peskin is a world-leading scientist specializing in parent EFAs — termed PEOs — and their direct relationship to both cancer and cardiovascular disease. While advancing the scientific understanding of the role of essential fatty acids in the body's metabolic pathways, he has concurrently developed a means for alleviating cancer's prime cause, as postulated by Nobel Prize-winner Otto Warburg, M.D., Ph.D., by increasing cellular oxygenation (The Hidden Story of Cancer, www.pinnacle- press.com). Amazingly, there is a fundamental cancer / heart disease connection, whereby the same physiologic solution solves both conditions. This information will lead to a new understanding of how to treat and prevent both cancer and heart disease. The basis for Peskin’s current work, grounded strictly in state-of-the-art science — in particular, physiology — can be found in his seminal work and peer-reviewed medical journal articles. Clinical physicians throughout the world have validated Prof. Peskin’s EFA recommendations. In the most exciting development to date, Brian’s theoretical conclusions were recently and completely validated in a physiological experiment by precise instrumentation capable of measuring arterial compliance. This experiment (IOWA study) provided the first conclusive clinical proof and validation of Prof. Peskin's theory. Peskin Pharmaceuticals has a patent pending on the medicament that embodies this development. (The full paper is here.)

What is a Parent Essential Oil (PEO)? 

There are only two (2) essential fatty acids, LA (parent omega-6) and ALA (parent omega-3). They MUST come from food. To work properly, they MUST be NOT heated, chemically unprocessed, organically raised and processed to guarantee full physiologic functionality. Fast foods use adulterated, non-functional EFAs that can no longer be termed a fully functional parent essential oils. All other EFAs excluding ALA and LA are correctly termed EFA “derivatives.” This includes the most common derivatives such as AA, DHA, EPA, etc. What is not understood by most physicians is that derivatives are made in the body, from the parent EFAs, on an “as needed” basis in extremely limited quantities. Consumption of derivatives from food is therefore not necessary, yet fish oil consists entirely of DHA and EPA in supra- pharmacological OVERDOSES, thereby overdosing the patient and causing damage instead of health. Few, if any, physicians ask to see the “normal standard” values of physiologic DHA/EPA amounts in tissue and plasma compared to the parent PEO amounts in tissue and plasma. When they discover the truth of how little DHA and EPA there should be in relation to how much they’ve been administering, physicians are shocked and dismayed that they have been (unknowingly) harming their patients, and wish to correct their recommendation to Peskin Protocol PEOs (as per the above physician testimonials). Peskin Protocol PEOs are a (patent- pending) plant-based proprietary formulation unlike any in the world and can be obtained organically from precise mixtures of sunflower, safflower, pumpkin, and evening primrose seed oils and coconut oil.

IOWA (Investigating Oils With respect to Arterial blockage) Study 

This is the first study using photoplethysmography to detail the differences in arterial flexibility between subjects taking PEOs and those taking fish oil. The results were staggering and shocking for those unfamiliar with Peskin’s work. IOWA is the first study conclusively proving the INFERIORITY of fish oil to PEOs as regards cardiovascular protection. 

The IOWA study (whose testing center is in Des Moines, Iowa) is run under the direction of Prof. Peskin (of Houston, Texas) in conjunction with renowned interventional cardiologist David Sim, M.D. (of Boise, Idaho). 

Long-term PEO supplementation in patients presenting with a broad spectrum of maladies resulted in: 35 subjects, 13 male and 22 female, aged 35-75. The median age was 62 years old. These volunteers were supplemented with plant-based essential fatty acids of the Peskin Protocol formulation for a period of 3 months to 48 months. 

The median duration of use was 24 months. Half of the subjects used the PEO formulation for less than 24 months and half used it for more than 24 months. Twenty-five of the subjects improved their arterial flexibility. That’s a stunning 73% effectiveness (absolute — not relative). The average improvement was a 9 year decrease in biological arterial age, making their effective age younger than their physical age. 

What is outstanding is the NNT (number needed to treat to see an effect in just one person) was 1.4. Pharma considers an NNT of less than 50 a good result for the effectiveness of their drugs. For example, for statins, the NNT to “prevent” one cardiovascular event is >80. That means more than 80 people would need to take a statin to see a single positive outcome. In contrast, just 1.4 people taking parent essential oils are required to see a positive outcome in 1 person. The statistical significance of the study, according to Alex Kiss, PhD, a statistician who has worked as consultant to the National Institute of Health (NIH) and is co-author of numerous peer-reviewed medical journal papers, including New England Journal of Medicine and Cancer, is extremely high (99.85%), compared to most studies, which come in at only 95%. This study is 30 times more accurate than the average clinical study. That means the results can’t be due to chance or error. The mean (average) arterial (biological) age of the subjects dropped over 8.8 years — making each of them in effect a younger patient! 

Predictable failure of fish oil In a completely different group of subjects, fifteen (15) subjects (7 males and 8 females aged 46- 74, average age was 60 years old) were consuming fish oil supplements for at least 6 months prior to switching to PEOs. Baseline analysis was performed prior to switching to PEOs. After an average time duration of PEO use of only 3.5 months, another scan was performed. Thirteen (13) of the 15 patients improved. That’s an 87% effectiveness rate, a NNT of only 1.2, and a reduction in biological arterial age of 11.1 years, measured by standard population samples. One subject remained unchanged, and one subject worsened (by a mere 1 year, which is statistically irrelevant). The statistical significance was 99.99%. 

CONCLUSION: you can take this result “to the bank.” 

It gets even more exciting. In subjects with high cholesterol, simply replacing their fish oil with PEOs improved 6 of the patients. Here the NNT to improve the vascular system in those with high cholesterol was an incredible 1.2. One subject with both diabetes and high cholesterol improved. Again, statins would need more than 80 people treated to effect one less cardiovascular event, an NNT of 80 (at best, as some studies show statins have an NNT of 300+). In two patients on statins, both improved their arterial flexibility by 20 years with the PEO formulation. Here, we have a group of people across all walks of life – no special groups were used and no particular groups were excluded. Using fish oil, the biological mean (arithmetic average) arterial biological age was 49. After using PEO, it fell to 38 — 11 years YOUNGER. 

CONCLUSION: compared to PEOs, fish oil worsens the cardiovascular system

Amounts of EPA/DHA in fish oil  

It is common amongst fish oil capsule manufacturers to have in excess of 300 mg of EPA and over 200 mg of DHA, with insignificant amounts of other omega-3 derivatives. They typically recommend 2 capsules each day for a total of over 600 mg EPA and 400 mg DHA daily. Three grams of PEOs per day is the general prophylactic dosage. Therefore the amount of parent omega-3 (ALA) is approximately 1,000 mg. Given that 2% maximum of this would be converted into the omega-3 derivative DHA, that would mean the body would naturally convert only 20 mg to DHA. Contrast this with the fish oil dosage of more than 400 mg, i.e., a DHA pharmacological overdose by a factor of 20! EPA overdose is even worse, as only 0.26% of ALA is normally converted. Of the 1,000 mg of ALA in Peskin Protocol PEOs, just 2.6 mg is converted, whereas the fish oil supplement provides over 600 mg or a 250-fold pharmacological overdose of EPA. This is analogous to giving the patient 250 aspirin tablets — you would kill him! Krill oil has less of the overdose amounts (approximately 130 mg EPA and 70 mg DHA per capsule) but it is still quite harmful. Given these facts, is it any wonder that fish oil categorically fails in experimental tests? No, of course not. Recommending these pharmacological overloads without compensating PEOs or omega-6 based derivatives is even worse, because of the gross disparity between the omega-6 and omega-3 series derivatives. Fish oil is harmful to most patients and the IOWA study proves its enormous NEGATIVE effect in the cardiovascular area.

Photoplethysmography (PTG) / Digital Pulse Analysis (DPA) and why I trust it 

Photoplethysmography (PTG) is a noninvasive method to measure arterial compliance (flexibility). Processing of this waveform by digital pulse analysis (DPA) affords clinicians a superb diagnostic tool. “Hardening of the arteries” is a prime cause of heart disease. Therefore, reversing or eliminating hardening of the arteries leads to significantly less patient heart disease. A digital pulse analyzer (DPA) can measure arterial flexibility. This device is simple. You put your finger in a plastic clip. It emits a soft laser light into your fingernail, much like an oxygen analysis with the common pulse oximeter. The waveform it reads is an incredibly accurate measure of the elasticity (or stiffness) of both your large (aorta) and small arteries of the cardiovascular system. Arterial rigidity is a direct reflection of arterial damage and arteriosclerosis. Computer software analysis allows simple and precise computation of the speed and volumes of the blood along with the associated waveforms over time. Mathematically, second derivatives (a tool of calculus) of the PTG waveforms are then taken to produce another waveform termed an accelerated plethysmograph (APG). This output is compared with outputs of known population values so it is easy to provide a “biological age” of the arteries based on already scanned populations. Supplementation with PEOs resulted in substantial improvement in arterial flexibility — i.e., a younger patient.

To read the full 10 years of Brian Peskin's work, link here.

To purchase YES EFA supplements developed by Brian Peskin, link here.